T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1076
Oneok
OKE
$58.4B
| $40.6M | ﹤0.01% |
691,546
-26,458
| -4% | -$1.64M |
|
1077
Helen of Troy
HELE
$696M
| $40.3M | ﹤0.01% |
164,830
-96,018
| -37% | -$22.8M |
|
|
RPC
1078
Ridgepost Capital
RPC
$972M
| $40.2M | ﹤0.01% |
+2,875,574
| New | +$37.9M |
|
1079
Hain Celestial
HAIN
$53.9M
| $39.9M | ﹤0.01% |
936,484
-2,838
| -0.3% | -$121K |
|
1080
Hilton Grand Vacations
HGV
$3.49B
| $39.8M | ﹤0.01% |
764,700
-1,429
| -0.2% | -$71.5K |
|
1081
Lyell Immunopharma
LYEL
$347M
| $39.8M | ﹤0.01% |
257,065
+74,101
| +41% | +$16.5M |
|
1082
New Oriental
EDU
$8.33B
| $39.8M | ﹤0.01% |
1,892,903
+12,000
| +0.6% | +$259K |
|
|
ARCE
1083
DELISTED
Arco Platform Limited Class A Common Shares
ARCE
| $39.7M | ﹤0.01% |
1,901,530
+284,630
| +18% | +$5.53M |
|
1084
Teradata
TDC
$2.57B
| $38.9M | ﹤0.01% |
916,717
+19,702
| +2% | +$972K |
|
1085
Edison International
EIX
$27.2B
| $38.8M | ﹤0.01% |
569,178
-1,056,163
| -65% | -$67M |
|
1086
Alector
ALEC
$228M
| $38.8M | ﹤0.01% |
1,876,848
+9,950
| +0.5% | +$224K |
|
1087
The RealReal
REAL
$1.33B
| $38.7M | ﹤0.01% |
3,335,479
-19,225
| -0.6% | -$253K |
|
|
KAHC.U
1088
DELISTED
KKR Acquisition Holdings I Corp. Units, each consisting of one share of Class A Common Stock and one-fourth of one redeemable warrant
KAHC.U
| $38.7M | ﹤0.01% |
3,861,073
-146,400
| -4% | -$1.47M |
|
1089
CareDx
CDNA
$2.45B
| $38.6M | ﹤0.01% |
848,813
+77,404
| +10% | +$4.04M |
|
1090
Box
BOX
$4.48B
| $38.5M | ﹤0.01% |
1,470,626
-66,090
| -4% | -$1.7M |
|
1091
CAE Inc. Common Shares
CAE
$8.9B
| $38.5M | ﹤0.01% |
1,524,533
-49,300
| -3% | -$1.38M |
|
1092
Synchrony
SYF
$26.1B
| $38.4M | ﹤0.01% |
828,563
-45,534
| -5% | -$2.19M |
|
1093
Dover
DOV
$28B
| $38.2M | ﹤0.01% |
210,568
-6,952
| -3% | -$1.18M |
|
|
SPNS
1094
DELISTED
Sapiens International
SPNS
| $38.2M | ﹤0.01% |
1,107,913
+909
| +0.1% | +$31.3K |
|
1095
Red Robin
RRGB
$183M
| $38.1M | ﹤0.01% |
2,304,663
-304,220
| -12% | -$5.82M |
|
1096
Bilibili
BILI
$7.14B
| $38M | ﹤0.01% |
818,672
-3,958,047
| -83% | -$265M |
|
1097
CONMED
CNMD
$1.49B
| $37.8M | ﹤0.01% |
266,942
+20,226
| +8% | +$2.86M |
|
1098
Addus HomeCare
ADUS
$2.2B
| $37.7M | ﹤0.01% |
403,652
-1,759
| -0.4% | -$158K |
|
1099
Ziff Davis
ZD
$1.92B
| $37.7M | ﹤0.01% |
339,786
-8,999
| -3% | -$1.07M |
|
1100
Akamai
AKAM
$18B
| $37.6M | ﹤0.01% |
321,306
-15,269
| -5% | -$1.68M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.